

1/13

Manufacturing process of coated deferasirox
tablets prepared by wet granulation





FIG.1

2/13




3/13

Dissolution profile of ICL670 from enteric coated tablets
prepared by Wet Granulation

Dissolution profile of ICL670 375 mg
WG variant after enteric coating

—▲ ICL670 WG Tablets 375 mg
(Enteric coated), Disso –
2 step pH 2–pH 6.8

**FIG.3**

4/13




FIG.4

5/13





FIG.5

6/13

Dissolution profile of deferasirox capsules consisting of enteric coated pellets prepared by extrusion spheronization.

**FIG.6**

7/13

Deferasirox mean concentration–time profiles in Clinical Studies 1–4

F2101




FIG.7A




FIG.7B




FIG.7C




FIG.8

11/13




FIG.9

12/13




FIG.10

13/13




FIG.11